Ovarian Serous Cystadenocarcinoma — Trials

Ovarian Serous Cystadenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

27 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	active not recruiting	Phase 1	50	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials

Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials